Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Flick

Nephrology Peoria, AZ Medical Doctor

NPI 1215921135 CMS profile 326662

7362 W Thunderbird Rd, Peoria, AZ 85381

Open in the dashboard

General payments

$529

11 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Flick of Peoria, AZ is reported in the CMS Open Payments database as having received $529 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $128 1
2024 General $260 3
2022 General $23 1
2020 General $61 3
2019 General $57 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Flick
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Richard Flick were reported at $128. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Richard Flick Nephrology median Middle half National median
2019 $57 $236 $90–$588 $163
2020 $61 $135 $46–$364 $114
2021 $0 $202 $67–$551 $132
2022 $23 $242 $77–$695 $149
2023 $0 $254 $84–$766 $160
2024 $260 $300 $99–$852 $164
2025 $128 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vantive US Healthcare LLC $128 1 payment
  2. Baxter Healthcare $124 1 payment
  3. NxStage Medical, Inc. $119 1 payment
  4. AstraZeneca Pharmaceuticals LP $77 4 payments
  5. Horizon Therapeutics plc $23 1 payment
  6. Akebia Therapeutics Inc $23 1 payment
  7. Relypsa, Inc. $18 1 payment
  8. Retrophin, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $512 10 payments
  2. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. NXSTAGE SYSTEM ONE $119 1 payment
  2. LOKELMA $77 4 payments
  3. KRYSTEXXA $23 1 payment
  4. Auryxia $23 1 payment
  5. Veltassa $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

3,252

Median for Nephrology: 954

Drug cost

$147,735

Median for Nephrology: $127,050

Branded share of claims

7.4%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 34 $37,419
Farxiga Dapagliflozin Propanediol Brand 42 $36,917
Sevelamer Carbonate Generic 43 $11,947
Calcitriol Generic 371 $9,258
Aliskiren Aliskiren Hemifumarate Brand 13 $7,141
Famotidine Generic 210 $4,188
Febuxostat Generic 20 $3,837
Calcium Acetate Generic 22 $2,231
Losartan Potassium Generic 211 $2,110
Amlodipine Besylate Generic 278 $2,010

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$302,175

Of which drugs: $7,561

Medicare patients

621

Average age 75

Services billed

7,576

339 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Arthritis 56%
Diabetes 54%
Ischemic heart disease 50%
Heart failure 37%
Atrial fibrillation 31%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 Office 20 2,220 $5,260
Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 Office 20 347 $2,301

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record